h1.qusth1 { display: none !important; }

QUESTION OF THE WEEK

Dr. Donovan's Articles

QUESTION OF HAIR BLOGS


Mice, Men and Evolving The Story of Topical Rosemary For Hair Loss

Topical Rosemary Helps Males and Mice with Hair Loss: Anything Else is Simply A Guess


There is a lot of excitement around the use of topical products containing Rosemary oil for hair loss. The reality is that we’re still not really sure how to use rosemary and we’re still not sure it truly helps all that much. A new study created some “buzz” as it showed rosemary helped grow hair in mice. This study is yet another study in the growing list of studies pointing to a favourable role for rosemary. Let’s take a look at the 2015 study that created quite a bit of interest in rosemary oil and then the new study in mice. We’ll come to see that we still don’t really know if rosemary helps that much.


Panahi et al 2015

This was a randomized controlled study of 100 male patients with androgenetic alopecia. (No females were included in the study - this is strictly a study of males). 50 males applied minoxidil 2 % (not 5 %) twice daily and 50 males applied rosemary oil twice daily. They did this for 6 months.

At the end of the 6 months, hair density increased very slightly from 138.4 hairs per cm2 to 140.7 hairs per cm2 in the minoxidil group and 122.8 to 129.6 in the rosemary group. 24 % of males in the minoxidil group felt they had mild improvement and 38 % in the rosemary group felt they had mild improvement. Nobody in either group felt they had moderate improvement. There were no changes in the perception of greasy hair or dandruff but both groups reported more scalp itching. The itching was greater for minoxidil users than rosemary users.

All in all, the conclusion was if you are male and willing to use rosemary oil twice daily, it may help your hair a little bit. Improvements will be very mild and not any better than 2% minoxidil. Likely 5 % minoxidil is better than rosemary oil given than we know 5 % minoxidil is better than 2 % minoxidil We can’t comment on the effectiveness in females as that was not studied here.


Begum A et al. 2023

A new study in mice showed that a 1 % rosemary lotion was just as helpful as 2 % minoxidil in promoting hair growth in mice. Hair was removed from a 3 cm2 hair from mice using a depilatory cream. Then mice were divided into 3 groups. One group received rosemary lotion on the hairless area twice daily. One group received 2 % minoxidil lotion twice daily and one group receive water (control) twice daily for 30 days. After 30 days, hair regrowth was studied. All in all, hair regrowth was pretty similar in mice treated with 2 % minoxidil and 1% rosemary - and far superior to water


Conclusion

All in all, rosemary is proving itself to have some use in hair regrowth. It’s a pretty mild growth stimulator at best and needs to be applied twice daily. It’s probably not as good as 5 % minoxidil. Just all all treatments, this will need to be done forever in the setting of androgenetic alopecia. We know that rosemary helps males and mice - but we have zero evidence it does anything for females. So, you and I are just guessing if we think it helps women with hair loss. I imagine that it does but that’s just a guess. Rosemary oil can irritate so we’ll need to warn patients about this.


REFERENCES

Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial.Skinmed. 2015 Jan-Feb;13(1):15-21.

Begum A et al. Evaluation of Herbal Hair Lotion loaded with Rosemary for Possible Hair Growth in C57BL/6 Mice. Adv Biomed Res. 2023 Mar 21:12:60.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Spironolactone: Should we also be checking zinc?

A study from Japan examined risk factors for zinc deficiency. The researchers used a study population of 13,100 patients who had reliable data available for zinc levels. Interestingly, associations with zinc deficiency were noted among older adults, males, and inpatients.

Following multivariate analysis, after adjusting for age and sex, there were significant associations with comorbidities, including pneumonitis (adjusted Odds Ratio (aOR) of 2.959), decubitus ulcer and pressure area (aOR 2.403), sarcopenia (aOR 2.217), COVID-19 (aOR 1.889), and chronic kidney disease (aOR 1.835).

What was particularly interesting to me as a hair specialist were the associations with certain drugs. Patients using the following medications were most likely to develop zinc deficiency: spironolactone (aOR 2.523), systemic antibacterials (aOR 2.419), furosemide (aOR 2.138), antianemic preparations (aOR 2.027), and thyroid hormones (aOR 1.864).

Comment

Zinc deficiency can cause a number of issues in humans. Globablly, zinc deficiency is said to affect 2 billion people.

Hair specialists need to know about zinc deficiency given that low zinc can sometimes cause hair loss or at least impact how hair grows.

Spironolactone was surprisingly a top drug in the list of drugs linked to zinc deficiency. More studies are needed to determine if hair loss patients using spironolactone are at risk for zinc deficiency and if we really should be checking zinc levels more often than we tend to do so now.



REFERENCE


Hirohide Yokokawa et al. Demographic and clinical characteristics of patients with zinc deficiency: analysis of a nationwide Japanese medical claims database. Sci Rep. 2024 Feb 2;14(1):2791. doi: 10.1038/s41598-024-53202-0.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Baricitinib (Olumiant) Now Approved in Canada for Alopecia Areata

on Friday Jan 26, 2024, Health Canada approved baricitinib for the treatment of severe alopecia areata. This makes it the second approved JAK inhibitor in Canada. Ritlecitinib was approved in early December 2023. Baricitinib is sold under the name Olumiant and Ritlecitinib is sold under the name Litfulo. Our DonovanMedical youtube channel has extensive discussion of both drugs.

VIDEO DISCUSSING RITLECITINIB

VIDEO DISCUSSING BARICITINIB


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Androgenetic Alopecia: What works?

Article from Cutis Now Published

I appreciated the opportunity to be invited by the journal Cutis to publish on androgenetic alopecia. This article can be downloaded in the following link

Donovan, J. Androgenetic Alopecia: What works? Cutis 2024.

For more information visit the Cutis website.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Year End Challenge 2023

Year End Challenge: Myocarditis Following Adenoviral Infection

In keeping with our year end tradition, the following situation was posted on our social medial channels. Participants had the opportunity to guess what was going on and how to help David.

CHALLENGE CASE

David is your healthy 28 year old male patient. He is on 5 mg of oral minoxidil and 0.5 mg dutasteride for treating hair loss.  He leaves a message on your office answering machine on new year’s eve wanting to know what he should do to help his feet swelling and dizziness. There is nobody in the office to take his phone call but he decides to leave a voicemail message.

David says on his message that he has been on oral minoxidil for 9 months and dutasteride for 2 years and absolutely loves his results. He is terrified to stop these drugs but feels they are now starting to cause major problems. He feels these drugs are delaying his recovery from a recent illness and maybe making everything worse.

He tells you in his message that he had a respiratory tract infection 4 weeks ago after attending a family reunion celebration. At the time, David says he had high fever, cough, runny nose. After a few days of feeling sick, David said he felt better for the next 7 days. David says he started feeling so much better that he went out to a party with friends about 1 week ago. He left the party early as he was tired. 

David says things have now worsened to the point where he needs to call you at the office. He continues to be very tired. He tells you has now had 7 straight days of heart burn. He says it started soon after going out drinking and partying with friends last week. He now has mild chest pain and you can hear him coughing on the answering machine message. He has gotten quite dizzy today and feels a bit short of breath. All in all, David feels oral minoxidil is somehow too strong for him and wonders if he should return back to using 2.5 mg. He tells you he notices a sock line so there may be ankle swelling.  He has  not examined it too closely as it’s not very comfortable to be moving around and bending too much.

He tells you that when he first started oral minoxidil 9 months ago at 2.5 mg he had no problems at all. He says he did have problems for a few days when he increased the dose up to 5 mg and he specifically remembers having dizziness and a chest tightness at that time. This lasted only a few days and he has been fine since. He likes oral minoxidil. He feels dizziness is somehow coming back and the mino pill is acting stronger than it really is. 

David says that his two sisters and his mother and 97 year old grandfather were also sick after attending the family reunion 4 weeks ago. He says everyone has completely recovered.  He generally considers himself very healthy so this is all confusing as to why he is not better yet.

David says his friend uses oral minoxidil and had similar symptoms of chest tightness and ankle swelling and needed to reduce the dose to 3.75 mg. His friend had to stop dutasteride because of feeling low energy so he wonders if dutasteride is somehow also causing problems.

David concludes his message by thanking you for listening to his long message and closes by asking “What should I do?”

What would you advise David?

ANSWER TO CHALLENGE CASE

This is a case example of viral myocarditis from the pre-COVID era. The cause here was adenovirus.

Myocarditis refers to inflammation of the heart layer known as the myocardium. Patients with myocarditis can present with a variety of symptoms.  

Most cases of myocarditis are identified in young adults  20-40 with males affected more often than females. Children and adolescents can also have myocarditis and sometimes have a serious course.

Myocarditis must also be considered in patients with shortness of breath, dizziness and especially loss of consciousness. It’s not the only disease that causes these symptoms of course.

Symptoms such as shortness of breath, fatigue and ankle swelling are concerning as they indicate possible heart failure.

 

Signs and Symptoms of Viral Myocarditis: What do patients experience?

It’s important to realize that there are no unique and specific symptoms that tell a doctor that a patient has myocarditis. Rather, it’s the constellation of symptoms that puts myocarditis on the list. Some patients with myocarditis feel chest tightness or a squeezing sensation.

 

Adults with viral myocarditis often have a 1-2 week history of a flu-like illness. Patients may have chest pain and shortness of breath. Fatigue, lower blood pressure, fever, tachycardia may be present.  Dizziness and general lightheadedness and even sycope are sometimes present. This may be  due to issues with the conduction system. There can be palpitations and flutters and in some cases even serious life threatening arrythmias.

If there is also pericarditis, then the patient may feel worse leaning back and feel better leaning forward.

Myocarditis can be caused by infections, vaccines, drugs. In the case of viral myocarditis, the patient develops symptoms a few days to weeks after a flu-like illness.  

Most cases of myocarditis are mild and improve with measures that help the heart function and treat conduction problems and rhythm issues.

 

What causes myocarditis?

Often the cause of myocarditis can’t be determined. In North America and Western Europe, viral infections are the most common identified causes of myocarditis. These include coxsackie virus, echo virus, human herpesvirus 6, parvovirus 19, adenovirus, enterovirus, cytomegalovirus, Epstein Barr virus, and influenza. COVID 19 is now a common cause of myocarditis as well. In some part of the world, bacteria and HIV are important causes.

 Drugs, toxins and autoimmune disease are among other causes.

 

How is myocarditis diagnosed?

There is no unique blood test that indicates myocarditis. Usually a patient with chest discomfort and shortness of breath will have several tests done in the emergency setting including troponin levels (a test of heart muscle damage), ECG, chest x ray and sometimes tests such as echocardiography. An elevated troponin without evidence that the patient is having a heart attack is often a tip off that myocarditis may be happening.

MRI is increasing used in diagnosing myocarditis. Only rarely is a heart muscle biopsy performed. This is a particularly risky test.

Myocarditis vs pericarditis: Are there differences in symptoms?

Myocarditis is inflammation of the myocardium (middle of the heart wall) where pericarditis is inflammation of the pericardium (a thin sac surrounding the heart). About one-third of patients with myocarditis also have pericarditis. Myocarditis and pericarditis have similar symptoms in many ways so there is a lot of  overlap. But there is some overlap.  It’s often said that pericarditis tends to  be more likely to severe chest pain, while myocarditis is more likely to cause fatigue and shortness of breath. There is overlap of course. The two can be better differentiated with ECG, clinical examination and MRI. In 50 % of cases of myocarditis, the exact cause is never found. In pericarditis, this is as high as 90 % of cases.

How is viral myocarditis treated?

Viral myocarditis is generally treated in what’s called a supportive manner. The patient’s blood pressure, heart rate, heart function is controlled using medications. This may be done in hospital or intensive care (ICU) setting in some cases. Some patients are very sick and require advanced ICU care.  NSAID and steroids are sometimes used in treatment. Colchicine is sometimes used in some cases of pericarditis.

Many cases of mild myocarditis and pericarditis resolve with supportive care.

 


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

WELCOME TO THE NEW EBHF PARTICIPANTS!

EBHF: 110 participants from 33 countries for 20 months .... with one main goal: … to develop a new level of expertise in the diagnosis and treatment of hair loss!

Just one week to go until I welcome 100 incredible hair loss specialists for a 20 month journey through the Evidence Based Hair Fellowship (EBHF) training program. Participants meet weekly online for a challenging but fun program that stimulates the brain to think and problem solve like an expert.

The journey starts off with 7 weeks of some of the most important material - the basic principles of hair loss diagnosis and treatment. We then journey through “blocks” of 1-2 month duration dedicated to subjects such as androgenetic alopecia, telogen effluvium, alopecia areata, scarring alopecia, hair shaft disorders, psychodermatology, traction alopecia, contact dermatitis, cancer, dysesthesias, hair transplantation and pigmentation. We discuss hair loss in children and infants and adults and pregnancy and older age.

We challenge ourselves each week with quizzes and tough cases and assignments.

In Aug 2025, we reach the finish line with a new set of skills to last a lifetime !

I am looking forward to meeting this amazing group of EBHF participants!


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Patients with Scarring Alopecia Are At Risk for Cardiovascular Disease

Males with Primary Scarring Alopecia are At Particularly Increased Risk

Authors of a new study set out to determine if patients with primary scarring alopecia are at increased risk to develop cardiovascular disease, coronary artery disease or stroke. The authors from Korea performed a nationwide longitudinal cohort study of 406,016 patients including 7,986 with primary scarring alopecia, 78,590 with non scarring alopecia and 319, 440 controls without hair loss. Patients were from the National Health Insurance Service (NHIS) database from 2013 to 2020. Patients were followed up until Dec 31 2020 or until they had a cardiovascular disease event or died.

The scarring alopecias studied included pseudopelade of Brocq (PPB), lichen planopilaris/frontal fibrosing alopecia (LPP), folliculitis decalvans (FD), dissecting cellulitis (DC). A category called cicatricial alopecia unspecified (CAU) was also included in this study.

The mean age of patients was 36.3 years, and 65.4% were men. Patients with PCA tended to have more underlying diseases and higher body mass index and FSG levels than controls.

 

 Patients with Scarring Alopecia have increased Risk for Heart Disease

After fully adjusting for potential confounders (like age, sex, household income, smoking, alcohol intake, physical activity, systolic blood pressure, fasting serum glucose, total cholesterol, and Charlson comorbidity index), patients with PCA had an increased risk of CVD (aHR 1.18; 95% CI 1.01-1.38) and CHD (aHR 1.26; 95% CI 1.02-1.55) compared to controls

 

Folliculitis Decalvans Patients

Patients with FD had an elevated risk of CVD (aHR 1.29; 95% CI 1.04-1.61) and stroke (aHR 1.39; 95% CI 1.05-1.84) compared to controls.

 

Lichen planopilaris/FFA Patients

Patients with LPP (aHR 1.93; 95% CI 1.07-3.49) had an increased coronary heart disease risk compared to controls.

 

Risk by Sex

When evaluated by sex it was found that males with PCA had a much greater risk of CVD, CHD and stroke compared to females. In fact, the risk was mainly in males

 

Conclusion

All in all, the authors found that patients with PCA had an increased CVD risk compared with controls without alopecia. In particular, among the subtypes of PCA, FD or LPP was significantly associated with an elevated risk of CVD, CHD, or stroke. Dissecting Cellulitis and Pseudopelade of Brocq did not appear to have any associated risk.

It’s not clear exactly why patients with scarring alopecia have this risk. It has been hypothesized that abnormal lipid metabolism might be a common link. It is well known that lipid metabolism dysregulation may be an important etiology for PCA . 

These data are important as it suggests that we need to think more carefully about how to help patients with PCA reduce their risk of CVD. This may be particularly important in males with scarring alopecia who are at greater risk.

 

REFERENCE

Kim SR et al. Association of Primary Cicatricial Alopecia with Subsequent Cardiovascular Disease. J Invest Dermatol. 2023 Nov 19:S


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Top 20 Hair Research Studies of 2023

Listen to the Recording of the Top 20 Studies of 2023

The following is a recording from the live webinar held Dec 13 2023. It is an annual webinar that celebrates that top 20 hair research studies of the prior year.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Autoimmune, Atopic, Metabolic, and Psychiatric Comorbidities in CCCA

Comorbidities in CCCA

 A new study showed that patients with CCCA have a higher prevalence of  autoimmune, atopic, metabolic, and psychiatric comorbidities. Prior studies have examined some of the cormorbidites that might exist with CCCA. Some of these studies suggested that CCCA is associated with several comorbidities including diabetes, metabolic dysfunction, bacterial scalp infections and uterine leiomyomas.

 

Joshi et al 2023

Authors of a new study set out to investigate comorbidities that are associated with CCCA. The database used was the National Institute of Health’s All of Us research program database.

There were 201 patients with CCCA.  Each patient with CCCA was matched to one age-, race-, ethnicity-, and gender-matched control. CCCA patients, compared to controls, were more likely to have metabolic abnormalities: hyperlipidemia (OR: 5.20, 95% CI: 3.37–8.03), hypertension (OR: 8.62, 95% CI: 5.46–13.59), and type 2 diabetes (OR: 5.66, 95% CI: 3.46–9.25).

CCCA patients were also found to have increased odds of having an autoimmune condition (OR: 4.92, 95% CI: 2.58–9.34).

CCCA patients were more likely to have atopic disease including allergic rhinitis (OR: 6.03, 95% CI: 3.54–10.26), asthma (OR: 3.55, 95% CI: 2.08–6.05), and atopic dermatitis (OR: 4.94, 95% CI: 1.40–17.47).

Regarding psychiatric conditions, there was also an  increased prevalence of anxiety (OR: 5.37, 95% CI: 3.39-8.52), and depression (OR: 3.23 95% CI: 2.10-4.98),  in CCCA patients, suggesting that CCCA may bear a negative quality of life impact.

 

Conclusion

Overall, the authors showed that CCCA patients have higher odds of autoimmune, atopic, metabolic, and psychiatric comorbidities.  The authors data match other studies showing the significancy increased risk of metabolic dysfunction.

The increased autoimmune conditions may suggest that abnormal T-cell licensing underlies the pathophysiology of CCCA. The increased allergies in CCCA may indicate the role of the T-helper-2 (Th2) cell axis in mediating CCCA.

Some studies suggested CCCA is associated with breast cancer and uterine leiomyomas. These were not studied here but would be valuable to note if this database could evaluate these risks.



REFERENCE

Joshi TP et al. Comorbidities in patients with central centrifugal cicatricial alopecia: a case-control study. . Int J Dermatol. 2023 Nov 23.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

1 in 5 Patients with Alopecia Areata Experience Workplace Bullying

Workplace Bullying Among Alopecia Areata Patients: Speaking up Leads to Negative Consequences for Some

Workplace bullying is a persistent pattern of mistreatment from others in the workplace that causes either physical or emotional harm.

Authors of a new study set out to better understand the frequency of workplace bullying among patients with alopecia areata and how bullying was addressed.

Authors used a questionnaire known as the Negative Acts Questionnaire-Revised Scale to assess bullying. This is a 22- item validated tool assesses workplace bullying within the last 6 months using a 5-point Likert scale corresponding to frequency of events. Scores range from 22 to 110 and correspond to being never bullied (<40), occasionally bullied (40–56), and severely bullied (>56)    

The questionnaire was administered to the National Alopecia Areata Foundation database to evaluate workplace bullying in patients with AA.

There were 673 patients who ultimately met the inclusion criteria completed the survey. Most respondents were female (n = 537, 79.8%) and Caucasian (n = 508, 75.5%) with an average age of 46.8 years. Most patients were employed full-time (n = 427, 63.4%)


1 in 5 Patients with AA are Bullied

21.67% (n = 146) of individuals with AA experience workplace bullying with an average NAQ-R score of 56.1. This corresponds to the cut off for being considered ‘severely bullied’

 

What are the more common types of bullying?

53.8% of patients with AA reported frequently having their “opinion ignored” and 47.7% reported  “being ignored or excluded” and 44 % reported the “spreading of gossips and rumors” by others.

What are the barriers to reporting bullying?


There were several barriers to reporting bullying

43.5 % identified the “stress associated with filing a complaint”

36 % of patients worried that reporting the bullying might have a negative effect on future career aspirations.

 

What proportion address the bullying?

Among individuals who self-reported bullying (n = 160), 75.0% (n = 120) chose to address the behavior.

What do people do when bullied?

The most common action when bullied is to discuss it with a manager. Some also discussed with family and friends. 25 % of patient did not take any action. Other options include those shown here:

What are the Consequences when Patients Take Action?

The most common consequences of addressing the bullying behavior were “the behavior continued” (30.8%, n = 37) 28.3 % of patients left their job. Other responses are shown below.

Comment

Workplace bullying is an important problem for patients with alopecia areata. About 1 in 5 patients report bullying. It’s not easy to report bullying. Patients report that there are stresses associated with filing a complaint and there are potential effects on future career options. Some bullying was noted to continue even after some individuals addressed the behavior.

There is an important and urgent need to develop strategies to reduce bullying. This may start with helping patients recognize all the aspects of workplace bullying and helping them to understand their options when this occurs. Strategies may also include continued education of the public and workplace.

 




REFERENCE

Li SJ et al. Experiencing Workplace Bullying in Patients with Alopecia Areata: A Cross-Sectional Survey Study. Skin Appendage Disord. 2023 Aug;9(4):258-261.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Do vaccines trigger Alopecia Areata ?

Do vaccines trigger AA?

Recently published reports from some parts of the world have reported the onset of AA in some individuals who received the COVID-19 vaccination. We’ve been covering this topic for a while now.


Chen et al 2023: Vaccine's Don’t Increase AA Risk and May even Decrease It

A study by Chen and colleagues examined the question “do vaccines increase the risk of developing alopecia areata?”

The authors performed a retrospective cohort study of patients with AA diagnosed at Arrowhead Regional Medical Center (ARMC) in Colton, CA at the demographic levels of age group, sex, and race. All cases of initial diagnosis of AA at ARMC occurred between December 17, 2020, and February 10, 2023. The study period was chosen to include the period from the initial COVID-19 vaccination administration to the time of data acquisition for this study.

Between December 17, 2020, and February 10, 2023, 1,402,255 residents had been either fully or partially vaccinated for COVID-19, while 785,250 had not received a vaccination at all. Over the same period, 73 patients at the medical center received an initial diagnosis of AA. Of those 73 patients, 36 had not received a COVID-19 vaccination before the diagnosis of AA, while 37 had been either partially or fully vaccinated for COVID-19. The incidence of AA calculated with the provided 73 AA patients in a 1,402,255 population is roughly 0.0052%

The probability of acquiring AA was lower in the vaccinated group overall, with an OR of 0.58 (95% CI = 0.35 to 0.94) and a p-value of 0.02. The risk of AA was also lower among the vaccinated females, with an OR of 0.32 (95% CI = 0.16 to 0.62) and a p-value of <0.05.

SOURCE: Chen J et al. The Incidence of Alopecia Areata in a COVID-19- Vaccinated Population: A Single-Center Review. Cureus 2023. Used with creative commons license.

 

Conclusion

This is an interesting study. It points to the possibility that vaccines don’t increase the overall risk of developing AA – at least in this part of the United states. These types of studies are challenging to conduct and interpret and the authors don’t exclude the possibility there are confounding factors here or limitations to the conclusion. Nevertheless, the study provides helpful information that by evaluating over 2 million patients living in a certain area – the risk of new onset AA did not seem increased.

The study does not evaluated whether vaccines flare existing AA or whether there are groups where the vaccine decrease AA and groups where it might increase AA.



Reference

Chen J et al. The Incidence of Alopecia Areata in a COVID-19- Vaccinated Population: A Single-Center Review. Cureus 2023


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

New Study Describes Varied Presentations and Disease Associations with Acne Keloidalis Nuchae  

Acne Keloidalis Nuchae: New Study Highlights Complexity of Disease

 

Acne keloidalis is a chronic scarring alopecia characterized by the development of papules, nodules, plaques and/or tumorous masses – typically starting in the lower occipital area of the scalp. The cause is not clear although trauma to the scalp is thought to play a role including close shaving, friction, heat and humidity.

Authors of a new study set out to perform a retrospective and multicentre international review of 79 patients with a confirmed diagnosis of AKN. Patients were from Spain, Australia and Italy.

 

Patients Characteristics & Predisposing Factors

The study included 79 patients (75 men and 4 women) with a median age at diagnosis of 35 years were included. 42% were Caucasian, 8% middle eastern, 20 % African, 12 % African American, 14% south American and 5 % Asian.

In terms of predisposing factors, 38% had straight hair, 25% have wavy hair and 38% had curly hair.  In terms of prior triggers, prior use of a razor to the back of the scalp was noted in 41% of patients. 17% previously used a helmet.

 

Disease associations

18% were obese, 6% had high blood pressure, 13 % had high cholesterol, 5% had diabetes, 9% had acanthosis nigricans. 12% had keloids in other areas of the body (with median number being 3). 20 % had pseudofolliculitis barbae, 12 % hidradenitis, 14% acne conglobate, 1 % pilonidal sinus, 6% dissecting cellulitis, 20 % folliculitis decalvans.


Severity

In terms of severity, 59% of patients had discrete papules and nodules, 18 % had merged papules and nodules, 12 % had plaques and 12 % tumerous mass. In terms of severity according to height of involvement in the occipital region (Umar classification). 41 % were less than 3 cm, 33 % were 3-6.5 cm, 26 % were more than 6.5 cm  and none were widespread .

Straight hair was associated with less than 3 cm distribution of the lesions and wavy hair was associated with 3–6.5 cm distribution.


Treatments

The authors described an incredibly large array of treatments that were used in attempt to treat the AKN. Intralesional steroids was the most performed treatment modality followed by oral retinoids and oral  and topical antibiotics.

19% of patients had no improvement with treatment but a high proportion of patients did have improvement. 26% had mild improvement, 18% had moderate improvement and 37% had significant or complete improvement.

Patients with a less than 3 cm distribution of the lesions or with discrete papules and nodules had a greater probability of important or complete improvement after treatment in comparison to the more than 6 cm distribution of the lesions group and the patients with merged papules and nodules.

 


Discussion

I liked this study as it draws attention to an scarring alopecia that is still very much a challenge to treat. Its exact pathogenesis is also not clear.

There are limitations to this study. These include lack of a control group and also the lack of matching the grade of improvement with the therapeutic modality.

But  what I liked about this study is its focus on the complex disease associations that exist in AKN. It’s clear that features of the metabolic syndrome are very prevalent in AKN.  In this study, a high proportion have  overweight/obesity (66.7%) and dyslipidemia (13%), hypertension (6%) and diabetes (5%)

This study supports that general notion that metabolic syndrome is increased in AKN and this is therefore an important call to action for the patient.

 

A large study by Kridin et al in 2020 of 2677 patients with AKN and 13,190 controls also drew attention to the issue of metabolic syndrome. The prevalence of the MS was 3 times greater in patients with AKN than in control subjects (16.1% vs. 6.6).  Obesity demonstrated the strongest association with AKN (OR 3.00; 95% CI 2.75-3.28), followed by type 2 diabetes mellitus (OR 2.47; 95% CI 2.20-2.77), hypertension (OR 1.82; 95% CI 1.63-2.05), and dyslipidemia (OR 1.60; 95% CI 1.46-1.75).  

A 2017 study by East Innis et al found that the presence of any component disease of the metabolic syndrome (OR = 14, P = 0.008) and specifically hypertension (OR = 6.75, P = 0.036) were significantly associated with the extension of the lesions beyond the nape and occipital scalp.

 

Other follicular and scarring alopecias as common too. It’s well known that PFB is common in AKN and this study confirmed that 1 in 5 patients with AKN had PFB. But other scarring alopecias are common including folliculitis decalvans (20% and dissecting cellulitis (6%). So we should not be confused if we are diagnosing 2 conditions in our patients.

Components of the  follicular occlusion tetrad (hidradenitis, acne conglobata, dissecting cellulitis, pilonidal cysts) are found in a significant proportion of AKN patients.  Patients may not always tell us about these as they feel they are not related – so we must ask. These issues can be debilitating.

The study also reminds us that treatments are helpful for some patients with AKN. While It’s true that 1 in 5 patients had no improvement, nearly one third had complete improvement. This information is important as patients often ask me if it’s worth treating or not.

 

REFERENCE


Lobato-Berezo A et al. Acne keloidalis nuchae: An international multicentric review of 79 patients. J Eur Acad Dermatol Venereol. 2023 Nov 1.

Kridin K et al. Acne Keloidalis Nuchae and the Metabolic Syndrome: A Population-Based Study. Am J Clin Dermatol. 2020 Oct;21(5):733-739.

East-Innis ADC et al. Acne keloidalis nuchae: risk factors and associated disorders - a retrospective study. Int J Dermatol. 2017 Aug;56(8):828-832.




This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Dr Donovan joins Dr Del Rosso to Talk about Hair loss on The Derms and Conditions Podcast

Derms and Conditions Episode 66 Features Discussions about Hair Loss

I enjoyed the opportunity to join Dr James Del Rosso, esteemed US dermatologist and host of the wonderful “Derms and Conditions” podcast for 2 podcast episodes dedicated to … hair loss!

In part 1, we discuss alopecia areata, JAK inhibitors, trichoscopy and more.

Thanks to Dr Del Rosso and the Derms and Conditions podcast group for this kind invitation.

Listen on any of your favorite podcast platforms.

CLICK HERE TO LISTEN TO THE EPISODE


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Announcing the Top 20 Hair Research Studies of 2023

Donovan Hair Academy Announces Picks for the Top 20 Hair Research Studies of 2023

In keeping with the annual year-end tradition, Dr Donovan announces choices for the top 20 hair research studies of the past year. This year’s public webinar will take place Dec 13 at 5 pm PST (8 pm EST). The 20 studies will be discussed at the webinar.

Registration is required for the webinar and this can be done using the links below:

REGISTER FOR THE TOP 20 HAIR RESEARCH STUDIES of 2023

A recording of the webinar will be made available at a later date on the DonovanMedical youtube channel and broadcast to the Evidence Based Hair Podcast as well.

DERMATOPATHOLOGY

Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.

 

ANDROGENETIC ALOPECIA

Gupta AK et al. The relative efficacy of monotherapy with 5-alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta-analysis study. J Cosmet Dermatol. 2023 Jun 29

Jimenez-Cauhe J et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.

 

 

ALOPECIA AREATA

Gandhi et al. The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata. Dermatol Ther (Heidelb). 2023 Jan;13(1):285-298.

 

Li SJ et al. Experiencing Workplace Bullying in Patients with Alopecia Areata: A Cross-Sectional Survey Study. Skin Appendage Disord. 2023 Aug;9(4):258-261

 

Kazmi A et al. Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023 Apr 4;S0190-9622(23)00532-7.

 

King B et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023 May 6;401(10387):1518-1529.

 

George P et al. Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database., Dermatol Ther (Heidelb). 2023 Aug; 13(8): 1733–1746.

 

Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.

 

Chen J et al. The Incidence of Alopecia Areata in a COVID-19- Vaccinated Population: A Single-Center Review. Cureus 2023

 

TELOGEN EFFLUVIUM

Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol. 2023 Mar 8.

TINEA CAPITIS

Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.

 

COSMETIC DERMATOLOGY

Landau M et al. Nonscarring alopecia after temporal lifting technique with dermal fillers. JAAD Case Rep. 2023 May 12;37:30-34

GENERAL SCARRING ALOPECIA

Kim SR et al. Association of Primary Cicatricial Alopecia with Subsequent Cardiovascular Disease. J Invest Dermatol. 2023 Nov 19:S

LICHEN PLANOPILARIS

Lim SH et al.  Prevalence and Incidence of Comorbid Diseases and Mortality Risk Associated with Lichen Planopilaris: A Korean Nationwide Population-Based Study. Clin Exp Dermatol. 2023 Jul 11;llad235

FOLLICULITIS DECALVANS

Matard B et al. Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association. Br J Dermatol 2022 Dec;187(6):1026-1028.

DISCOID LUPUS

Fredeau L et al. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients. J Am Acad Dermatol. 2023 Mar;88(3):551-559.

 

DISSECTING CELLULITIS

Cajas-Garcia MS et al. Distinct presentations of scalp dissecting cellulitis manifesting with furrows and gyri. J Eur Acad Dermatol Venereol. 2023 Feb 3.

 

CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA

Joshi TP et al. Comorbidities in patients with central centrifugal cicatricial alopecia: a case-control study.  Int J Dermatol. 2023 Nov 23.

 

ACNE KELOIDALIS NUCHAE

Lobato-Berezo A et al. Acne keloidalis nuchae: An international multicentric review of 79 patients. J Eur Acad Dermatol Venereol. 2023 Nov 1.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

The 2D:4D Ratio: Nice Article Summarizes a Challenging AGA Literature

The 2D:4D Ratio

The measurement of the length of the second and fourth fingers has been argued by some to provide a crude measurement of exposure to androgens in utero and an estimate of risk of androgen related disorders. Some have proposed that a lower 2D:4D ratio may signify elevated levels of perinatal testosterone, thereby providing a surrogate marker of an increased risk to develop androgenetic alopecia. The 2D:4D ratio has been utilized to predict the risk of hyperandrogenism, increased body mass index and waist-to-hip ratio, and benign prostatic hyperplasia.

How to measure the 2D:4D Ratio

To measure the 2D:4D ratio, the lengths of second digit (index finger) and fourth digit (ring fingers) are measured from the fingertip to the midpoint of the basal crease, on the ventral surface of the hand. They are best measured using digital vernier calipers for greater accuracy. More commonly a ruler is done when sophisticated calipers are lacking. The 2D:4D ratio is obtained by dividing these values. Usually, two or more measurements are taken to ensure the greatest reliability. The mean of the multiple measurements are taken for right and/or left hand and divided for the calculation of 2D:4D ratio of the right and left hands separately. Some have argued that the right digit ratio is more differentiated and sensitive to prenatal testosterone exposure. Many researchers report an “averaged” 2D:4D ratio across both hands

Does the 2D:4D ratio Predict Androgenetic Alopecia?

A nice review by Almashali M et al. summarizes what we know about the 2D to 4D ratio in AGA. The authors show us that 4 studies have been published that address this issue. Three studies suggest a role for the 2D:4D ratio to predict AGA and one large study suggests there’s really not much evidence at all (except maybe in individuals over 40 years of age).

A study by Chen et al from 2022 showed that individuals with a right-hand 2D:4D less than 0.947 may have a more severe form of AGA (P = 0.036). The authors found that the marker really becomes even more reliable as one ages. In other words, older individuals with a low 2D:4D were more likely to have androgenetic alopecia.

The largest study on the subject was a 2016 study from Iran by Feily A and colleagues. The authors studied 1200 males with AGA and found no link between AGA and 2D:4D ratio. However, the authors did find that when data was stratified according to age, there was a positive correlation between a low 2D:4D and the risk of AGA in those older than 40 years of age. Taken together, the authors proposed that the the 2D:4D may not be used to determine a patient’s likelihood of developing AGA without also considering the patient’s age. it’s much more useful of a test in older adult males.

Table from

REFERENCE

Almashali M et al. The Use of 2D:4D Digit Ratio as a Predictor of Androgenetic Alopecia: A Review. Dermatol Pract Concept. 2023 Oct 1;13(4):e2023237.

Key Studies Referenced

Chen WC, Hsu WL, Chen JY, Shih NH, Wu CY. Second-to-fourth digit ratio and age predicting the severity of androgenetic alopecia: a cross-sectional study. Aging Male. 2022;25(1):242–248.

Feily A, Hosseinpoor M, Bakhti A, et al. Digit-Length Ratios (2D:4D) as a Phenotypic Indicator of in Utero Androgen Exposure is Not Prognostic for Androgenic Alopecia: a Descriptive-Analytic Study of 1200 Iranian Men. Dermatol Reports. 2016;8(1):6386.

Unal M. Digit ratio 2D:4D is a possible indicator for androgenetic alopecia in males. J Cosmet Dermatol. 2018;17(3):545–548.

Bilgic Ö, Altınyazar HC, Eryılmaz D, Tuğrul ZA. Are 2D:4D finger-length ratios an indicator of androgenetic alopecia in males? An Bras Dermatol. 2016;91(2):156–159.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Does age related macular degeneration occur more frequently in AGA?

Macular Degeneration May be More Common in Androgenetic Alopecia

Authors of a new study set out to evaluate whether patients with AGA are at risk for macular degeneration and whether simple blood tests for microinflammation could asses the risk.

To do so, the authors performed a case control study with 40 patients with AGA aged 40 years or more of both sexes and 40 control subjects. Patients underwent examinations of the skin and eyes. Blood tests were performed for a variety of tests including the monocyte to HDL ratio (MHR) which authors felt was a good marker of ‘microinflammation.’

The authors found that the mean MHR was significantly higher in AGA patients (6.98 ± 2.21) than in controls (3.82 ± 0.68) (P < 0.001). Surprisingly the authors found that 80 % of AGA patients were diagnosed with age related macular degeneration compared to just 20% of control subjects. Male patients with more severe AGA were more likely to have macular degeneration. Interestingly, the mHR was significantly higher in AGA patients found to have AMD (9.37 ± 1.1 and 7.01 ± 1.42 in the wet and dry type respectively) compared to patients without AMD (P < 0.001).

Conclusions and Discussion

This is an unexpected report. The authors suggest that macular degeneration may develop more frequently in those with androgenetic alopecia. Moreoever the authors propose that the MHR might serve as a potential biomarker for predicting AMD in AGA patients.

A Brief Overview of the MHR in Cardiovascular Diseases

For those not aware, I’d like to spend a moment talking about monocytes and HDL and how these all factor in when it comes to inflammation. Inflammatory cells known as monocytes are known to be major source of “proinflammatory” species during atherogenesis. In atherosclerosis, modified low-density lipoproteins (LDLs) are removed by macrophages; these are recruited in the vessel wall, inducing the release of inflammatory cytokines in inflamed tissue. Hence, inflammatory cholesterol ester-loaded plaque is generated.

High-density lipoprotein-cholesterol (HDL-C) exhibits “anti-atherosclerotic” effects by neutralizing the pro-inflammatory and pro-oxidant effects of monocytes. HDL does this by inhibiting the migration of macrophages and LDL oxidation in addition to the efflux of cholesterol from these cells. Furthermore, HDL plays a role in blocking the activation of monocytes and proliferation-differentiation of monocyte progenitor cells.

Taken together it has been proposed that the accumulation of monocytes and reduction of HDL-C may participate in atherosclerosis and cardiovascular disease.

MHR has been found to increase with age and with a variety of inflammatory diseases including fatty liver, insulin resistance, post stroke depression, resistance blood pressure problems, sleep apnea, pulmonary hypertension. In psoriasis, MHR is closely linked to the PASI (severity) score. These are only a short list of inflammatory conditions linked to MHR

REFERENCE

Shams GM et al. Age-Related Macular Degeneration in Patients with Androgenetic Alopecia: Could the Monocyte/HDL Ratio Be the Link? Dermatol Pract Concept. 2023 Oct 1;13(4). doi: 10.5826/dpc.1304a285.

Ganjali S et alMonocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. J Cell Physiol . 2018 Dec;233(12):9237-9246.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Baricitinib for Alopecia Areata: Eyebrows & Eyelashes Often Significantly Improve Even If Scalp Hair Does not

Significant Eyebrow and Eyelash Improvements in AA Treated with Baricitinib

Authors of a new study set out to re-examine the complete data from the BRAVE AA1 and BRAVE AA2 baricitinib trials to see if eyebrow and eyelash regrowth could still occur to significant levels even if scalp hair regrowth was not occurring. The authors examined eyebrow and eyelash regrowth patterns in patients with AA who had a poor response to scalp regrowth (SALT ≤ 20 response), intermediate response to scalp regrowth (achieved a 30% improvement from baseline (SALT30) without a SALT score ≤ 20), or non-responders (never achieved SALT30).

After 52 weeks of treatment with baricitinib 4 mg treatment, 70 % of scalp responders have complete or near complete regrowth of eyebrows and eyelashes. In contrast, complete or nearly complete regrowth of eyelashes and eyebrows occurred in 50% of patients with intermediate response and 20% of non-responders.

All in all, the authors found that clinically meaningful regrowth in eyebrow and eyelash hair can occur with baricitinib treatment even if scalp hair regrowth does not occur .

REFERENCE

Senna MM et al. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatol Ther (Heidelb). 2023 Nov 22. doi: 10.1007/s13555-023-01063-2. Online ahead of print.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Topical Minoxidil as a Cause of Lung Disease

Another Case of Minoxidil Induced Lung Disease

The side effects of minoxidil do not typically include anything to do with the lungs. Typical side effects of topical minoxidil include shedding, irritation, palpitations, hypertrichosis. Rare side effects include chest pain, facial swelling, parasethesias. Oral minoxidil side effects include fluid retention in the feet and rarely the body as well as hypertrichosis, dizziness, palpitations and headaches.

Earlier this year, we reviewed an interesting study of hypersensitivity pneumonitis from oral minoxidil. I have included a link to that study here:

Ishiguro et al. 2023

Authors of a new study report a patient with drug induced lung disease from topical minoxidil. The patient’s lung function and chest x ray was observed to worsen with minoxidil use and then improved when minoxidil was stopped. Thoracoscopic lung biopsy samples showed interstitial pneumonia and granulomas.

This is an interesting report which reminds us of the need for open mindedness when considering side effects of our hair loss drugs. Minoxidil is a generally safe medication with infrequent side effects. However, side effects can occur.

REFERENCE

Ishiguro T et al. Drug-induced lung disease due to topical minoxidil. Respir Med Case Rep. 2023; 46: 101940.


This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

5 % Minoxidil is Similarly Effective to 1 mg Oral Minoxidil

Another Study Supports Notion that 1 mg LDOM just as Effective as Topical 5 % Minoxidil

Prior studies have suggested that oral minoxidil is not always better than topical. For example, in 2020, Dr Ramos and colleagues showed that 1 mg oral minoxidil was similar in effectiveness to 5 % minoxidil in women.

Asilian et al. 2023

A new study from Iran shows similar findings to the Ramos study. Authors in this study randomized 65 patients (male and female) to either 1 mg oral minoxidil or 5% topical minoxidil (1 cc twice daily for men and 1cc once daily for women) for 6 months and looked at outcomes 6 months later. Hair improvements were similar in the two group and one group was not superior to the other. There were more patients in the oral minoxidil group who had low blood pressure and excessive hair growth but overall treatments were well tolerated in both groups.

All in all, this study lends support the concept that 5 % minoxidil and 1 mg oral minoxidil are likely to be similarly effective for treating androgenetic alopecia. The study is small and complicated by including both male and female patients and by including topical minoxidil and different doses (twice daily in men and once daily in women). Nevertheless, it lends support to the notion that topical minoxidil is not likely to be inferior to 1 mg oral minoxidil.


REFERENCE

Asilian A et al. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: A randomized controlled trial. J Cosmet Dermatol. 2023 Nov 29.



This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments

Deuruxolitinib Data Looks Good at Week 52

Response Data for Deuruxolitinib Looks Good at Week 52

Download PDF Version of this Article

Deuruxolitinib is a Janus kinase (JAK) 1 and JAK2 inhibitor. It has been studied in the THRIVE-AA1 and THRIVE-AA2 clinical trials. In these studies, adult patients with AA were randomized to 8 mg BID and 12 mg BID doses vs placebo. At 24 weeks, about 30 % of patients using deuruxolitinib 8 mg twice daily achieved good regrowth. In other words, they met the typical AA study endpoint that denotes good regrowth (ie SALT score less than 20).

Concerns were raised in 2023 with deuruxolitinib at the 12 mg twice daily dose. Blood clots in patients receiving these doses caused the FDA to pause clinical trials of deuruxolitinib. We’ve discussed these issues in the past and a link to prior articles is here:


Week 52 Data show 60 % of patients Meet SALT M<20 Endpoint

New data that was presented at a recent meeting of the European Academy of Dermatology and Venereology showed that an even greater number of patients achieve the SALT 20 endpoint by week 52 compared to week 24. Dr King presented week 52 data as part of the company’s open label study. Here, patients received either 8 mg BID or 12 mg BID oral deuruxolitinib. After 52 weeks of cumulative dosing, 63.6% of patients in the 8 mg BID group achieved a SALT score less than 20. This was similar (62.1%) in the 12 mg BID group.

Comments and Discussion

This is exciting data. It would appear that deuruxolitinib is effective in treating advanced AA. It’s a bit surprising that the 12 mg BID dosing and 8 mg BID dosing produce similar clinical outcomes. That’s not a dose response we typically see with our other JAK inhibitors. In other words, for most other JAK inhibitors, higher doses of the drug bring better results.

The time draws near that various regulatory bodies around the world will need to consider approving deuruxolitinib. I’d be surprised if any dose other than the 8 mg dose goes up for consideration. Personally, what’s left for me as a hair specialist is:

1) to closely follow over time if the safety of deuruxolitinib is the same as other JAKs,

2) to follow if deuruxolotinib is truly more effective than other JAKs or just as effective at 8 mg BID dosing over 2, 3 and 5 years of observation

and

3) what will be the final cost of this drug.

How does the 52 week Deuruxolitinib data compare to 52 weeks data for Baricitinib and Ritlecitinib?

The graph below shows the proportion of patients using baricitinib and ritlecitinib that achieve reasonably good regrowth (SALT <20) and includes data up to 1 year. It shows the proportion of patient who achieve 80 % regrowth (ie SALT less than 20). If 60 % of those treated with 8 mg BID deuroxolitinib achieve a SALT less than 20 that would put deuruxolitinib as a top performing JAK inhibitor - at least at week 52. I hope to review all the data at some point - everything on the table. Long term studies of safety as well as effectiveness are key for all JAK inhibitors but especially JAKs that have already been issued warnings in their trials. Similar to all JAK inhibitors, we’ll need to follow deuruxolitinib long term data on blood clots, cancer, heart disease and infections.



REFERENCE

ABSTRACT 6743 - https://eadv.org/wp-content/uploads/scientific-abstracts/EADV-congress-2023/Hair-and-nail-disorders.pdf




This article was written by Dr. Jeff Donovan, a Canadian and US board certified dermatologist specializing exclusively in hair loss.
Share This
No Comments



Share This
-->